A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging by Keren, Leeat et al.
A Structured Tumor-Immune Microenvironment in Triple 
Negative Breast Cancer Revealed by Multiplexed Ion Beam 
Imaging
Leeat Keren1, Marc Bosse1, Diana Marquez1, Roshan Angoshtari1, Samir Jain1, Sushama 
Varma1, Soo-Ryum Yang1, Allison Kurian1, David Van Valen2,3, Robert West1, Sean C 
Bendall1,*, and Michael Angelo1,*,†
1.Department of Pathology, Stanford University, Stanford CA, 94305
2.Department of Biology, Caltech, Pasadena, CA 91125
3.Department of Bioengineering, Caltech, Pasadena, CA 91125
Abstract
The immune system is critical in modulating cancer progression, but knowledge of immune 
composition, phenotype, and interactions with tumor is limited. We used Multiplexed Ion Beam 
Imaging by Time-of-Flight (MIBI-TOF) to simultaneously quantify in-situ expression of 36 
proteins covering identity, function and immune regulation at sub-cellular resolution in 41 triple-
negative breast cancer patients. Multi-step processing, including deep-learning-based 
segmentation, revealed variability in the composition of tumor-immune populations across 
individuals, reconciled by overall immune infiltration and enriched co-occurrence of immune 
subpopulations and checkpoint expression. Spatial enrichment analysis showed immune mixed 
and compartmentalized tumors, coinciding with expression of PD1, PD-L1 and IDO in a cell-type- 
and location-specific manner. Ordered immune structures along the tumor-immune border were 
associated with compartmentalization and linked to survival. These data demonstrate organization 
in the tumor-immune microenvironment that is structured in cellular composition, spatial 
arrangement, and regulatory-protein expression and provide a framework to apply multiplexed 
imaging to immune oncology.
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Abstract
Introduction
Cancer progression is a complex process that depends on the interplay between individual 
cells in the tumor, the microenvironment, and the immune system, which can act both to 
promote and suppress tumor growth and invasion (Chen and Mellman, 2017). 
Immunotherapy, and in particular antibodies that target regulators of immune activation such 
as CTLA-4, PD1, and PD-L1, have significantly improved survival in renal cell carcinoma, 
lung adenocarcinoma, and melanoma (Ribas and Wolchok, 2018). Triple-negative breast 
cancer (TNBC) is an aggressive form of invasive breast cancer, negatively defined by lack of 
appreciable expression of the therapeutic targets estrogen receptor, progesterone receptor, 
and Her2 (Denkert et al., 2017). Consequently, radiation and chemotherapeutic neoadjuvant 
therapy are the current standard-of-care treatment. Several studies have shown increased 
tumor infiltrating lymphocytes (TILs) in TNBC compared to other breast cancers and 
correlations between specific immune subsets and prognosis (Andre et al., 2013; Denkert et 
al., 2010; Disis and Stanton, 2015; Teng et al., 2015), leading to clinical studies of several 
immunotherapeutic agents in TNBC (Kwa and Adams, 2018). Although preliminary, overall 
response rates typically range 15–30%, similar to observations in gastric and head and neck 
cancers (Muro et al., 2016; Seiwert et al., 2016). Many diagnostics have been suggested to 
delineate responders from non-responders, including expression of immuno-suppressive 
proteins, such as PD-L1 (Patel and Kurzrock, 2015), infiltration by CD8+ T cells (Tumeh et 
al., 2014), and expression of inflammatory genes, such as IFN-γ (Gao et al., 2016; Zaretsky 
et al., 2016). So far, however, no single biomarker has been sufficient for adequate patient 
stratification, presumably due to the complexity of the immune response to cancer (Maleki 
Vareki et al., 2017). To date, there is limited understanding of the tumor immune landscape: 
which immune cell types are found in the tumor, which cells express distinct 
immunoregulatory proteins, and how these vary between patients.
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Tumors are spatially organized ecosystems that are comprised of distinct cell types, each of 
which can assume a variety of phenotypes defined by co-expression of multiple proteins. 
Thus, to interrogate solid tumor biology and response to treatment it is necessary to gauge 
the expression of a multitude of proteins with single-cell or even subcellular resolution while 
preserving spatial information. However, until recently, routine laboratory assays could only 
satisfy one of these two requirements – either measuring expression of one or two proteins 
in situ or many genes in cell suspensions from dissociated tissues (Chevrier et al., 2017; 
Matos et al., 2010). This disparity between our conceptual understanding of the tumor 
ecosystem and the experimental tools at our disposal has driven the recent developments of 
multiplexed imaging modalities (Chen et al., 2015; Coskun and Cai, 2016; Giesen et al., 
2014; Huang et al., 2013; Lee et al., 2014).
We have previously reported Multiplexed Ion Beam Imaging (MIBI), a method that uses 
secondary ion mass spectrometry to image antibodies tagged with isotopically pure 
elemental metal reporters in intact tissue sections (Angelo et al., 2014). We have since 
constructed a purpose-built instrument that utilizes high brightness primary ion sources, 
novel ion extraction optics, and time-of-flight mass spectrometry (TOF) to increase channel 
multiplexing and decrease acquisition times by 50-fold (Methods). MIBI-TOF now enables 
fully automated, 40-plex imaging of large fields of view (up to 1mm2) at resolutions down to 
260nm. It is compatible with a wide-range of sectioned tissues including formalin-fixed 
paraffin-embedded (FFPE) specimens, the primary preservation method of solid tissue 
biopsies in clinical anatomic pathology.
In this study, we leveraged MIBI-TOF to identify salient features demonstrating a structured 
tumor-immune microenvironment in a retrospective cohort of 41 TNBC patients. We imaged 
36 proteins, including tumor and immune antigens and immunoregulatory proteins, and 
developed an extensible deep-learning-based pipeline for standardized processing, 
segmentation, and quantification of cell-types. We captured large differences between 
patients in both the composition and total number of immune cells. While the size of 
immune infiltrate spanned over two orders of magnitude, it correlated with tumor vascularity 
and immune composition. Co-occurrence of distinct immune populations across patients, in 
accordance with infiltrate size, suggest a lineage-specific interdependence where the 
presence of one cell type is frequently accompanied by the other. Simultaneously, we also 
evaluated the expression of four immunotherapy targets (PD-1, PD-L1, Lag3, and IDO) by 
distinct immune and tumor cell subsets and found differential enrichments across patients, 
highlighting the importance of multiplexed analysis. For example, PD-1 was primarily 
expressed on CD4+ T cells in some patients and on CD8+ T-cells in others. Expression of 
multiple immunoregulatory proteins by the same cell was statistically enriched, and patients 
that express one immunosuppressive pathway were more likely to express another, with 
potential implications for combination immunotherapies. In addition, we developed a data-
driven approach to assess the spatial proximity of cell types in tissues. We found that tumors 
with similarly-sized immune infiltrates had different spatial organizations and divided the 
tumors into ‘Cold’ (no infiltrate), ‘Mixed’ (immune cells mixed with tumor cells) and 
‘Compartmentalized’ (immune cells spatially separated from tumor cells). These subtypes 
were associated with distinct tumor and immune populations expressing immunoregulatory 
proteins. Highly ordered structures with PD-L1 and IDO along the tumor-immune border 
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served as a hallmark of tumor compartmentalization and could be further linked to overall 
survival. Altogether, this work elucidates features of the tumor-immune microenvironment 
in TNBC and provides a starting framework for applying multiplexed imaging to uncover 
relational features of tumor, stromal, and immune cells in standard clinical specimens.
Results
Development of a multiplexed imaging assay for the tumor-immune microenvironment
The workflow for MIBI-TOF is comparable with that of conventional IHC (Fig. 1A). 
Clinical FFPE tissue specimens were placed on a slide and stained overnight using a single 
master mix of elementally-labeled primary antibodies (Bendall et al., 2011). All targets are 
stained together without the need for cyclical steps or enzymatic reactions. The slide is 
placed in the MIBI-TOF mass spectrometer (Fig. S1A), and the tissue is subjected to a 
nanometer-scale, rasterizing oxygen duoplasmatron primary ion beam. As this ion beam 
strikes the sample, elemental reporters conjugated to the antibodies are liberated as 
secondary ions, which are measured and quantified by a time-of-flight mass spectrometer. 
Thus, for each physical pixel in the tissue, a mass spectrum is recorded, representing the 
abundance of the antigens in that location (Methods).
We devised an antibody panel to interrogate 36 features of the tumor-immune 
microenvironment in TNBC (Fig. 1A, Table S1). The panel included tumor-related proteins 
(e.g. EGFR, p53), functional markers for proliferation and metabolic activity (e.g. Ki-67, 
pS6), immune-related proteins (e.g. CD4, FoxP3) and four immunoregulatory proteins 
(PD-1, PD-L1, LAG3 and IDO) currently targeted in the clinic or undergoing 
immunotherapy drug trials.
We performed several experiments to gauge assay sensitivity, specificity and repeatability. 
Antibody staining for each target was validated using six tissue types. Representative panel 
staining for tonsil, placenta, gastrointestinal tract and breast carcinoma are shown in Fig. 1B. 
Each antibody was tested across five or more titers with final titers selected to maximize the 
separation between signal and background (Methods). We first evaluated whether the 
staining of each antibody was specific to the known histologic distribution for each target 
and matched conventional imaging using immunohistochemistry (Fig. S1B). For example, 
bright epithelial staining for CK6 and CK17 was observed in morphologically distinct tumor 
cells in breast carcinoma, while very little was observed in the germinal or interfollicular 
regions in tonsil (negative staining not shown). CD20 primarily stained cells in the germinal 
center where B cells are the predominant population, while CD3 and CD4 primarily stained 
cells in the mantle zone, populated with T lymphocytes. (Fig. 1B,D–E). Second, we 
evaluated the subcellular localization of the different antigens. Expectedly, we find that 
transcription factors (e.g. Ki-67, FoxP3), are predominantly nuclear whereas membrane 
proteins (e.g. CD4, CD20) have low overlap with the nucleus (<10%, Fig. 1F,G). Third, we 
assessed the co-expression of proteins known to be expressed either on the same cell type or 
on different cell types. For example, consistent with T cell differentiation as either a helper 
(CD3+CD4+, Fig. 1H white arrows) or cytotoxic (CD3+CD8+, Fig. 1H yellow arrows) 
phenotype, we find that less than 3% of the CD3+CD4+ pixels are also CD8+ (Fig. 1H, 
S1C). Consistent with a T regulatory (Treg) phenotype, 99% of the FoxP3+ cells were 
Keren et al. Page 4
Cell. Author manuscript; available in PMC 2019 September 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
positive for CD4 (Fig. 1F). In order to quantify cross-talk between markers we stained three 
serial sections from tonsil using four sub-panels, each one with six distinct empty channels. 
For each sub-panel we verified that the empty channels gave less than 0.1% of the original 
signal (Fig. 1C). Finally, we asserted the high reproducibility of our system by staining serial 
sections from human lymph node (R=0.9, P<10−20 Fig. S1D). Altogether, our assay allows 
to robustly image 36 antigens at sub-cellular resolution with a dynamic range sufficient for 
quantifying both high and low-abundance proteins in intact FFPE human tissues.
Automated image analysis pipeline delineates ordered immune composition in TNBC
We applied MIBI-TOF to profile a tissue microarray of 41 TNBC patients treated at 
Stanford hospital between 2002–2015 (Table S2). All samples were stained simultaneously 
using a single antibody master-mix, and scanned together to reduce technical variability. For 
each sample, we profiled a region of 8002μm2, 2048×2048 pixels, at 500nm resolution, 
obtaining information on thousands of cells (3,000–10,000 across patients). All the data, 
encompassing 1763 images, is available at https://mibi-share.ionpath.com, in a user-friendly 
interface, facilitating browsing. An initial overview identified large inter-patient 
heterogeneity in tumor protein expression, such as Keratins, EGFR and HLA-DR (Fig. 1I, 
S1E–J).
We developed a computational pipeline for data analysis (Methods). For each field of view 
(FOV), the counts for each reporter in each pixel were extracted from the mass spectra and 
converted to a multi-dimensional TIFF which was background subtracted using a blank 
channel. Noise was filtered using a k-nearest-neighbor approach and batch effects were 
removed using quantile normalization (Fig. S2A–F). To segment the cells from the images 
we leveraged the high-dimensionality of our data to adapt DeepCell (Van Valen et al., 2016), 
a convolutional neural network (CNN) for nuclear segmentation (Fig. 2A, Methods). To train 
the network, we manually segmented the nuclei of two patients (~8M pixels). The network 
achieved a per-pixel accuracy score of 74% on the training set and 73% on the validation 
(Fig. S2G). We applied the trained network to all patients in the cohort and output 
probability scores were post-processed to generate the final segmentation mask. The CNN 
approach yielded dramatically improved results compared with alternative methods tested 
(Fig. S2H). Following segmentation, we extracted the single-cell expression values for all 
the markers and clustered the cells from all patients (Van Gassen et al., 2015) (Fig. 2A, S2I).
To chart the immune landscape in TNBC we quantified the number of immune cells per area 
across patients and found large variability, spanning more than two orders of magnitude 
(Fig. 2B). This variability was confirmed by pathological TIL scoring on H&E staining of 
the entire cohort, as well as H&E staining of an additional core for patients 1–14, to 
establish low contribution of intra-patient variability in immune infiltration to these results 
(Fig. S3A–B, Table S2). To control for differences in absolute cell counts, we also quantified 
the fraction of immune cells in the field, which accordingly ranged from 1% to 91% (Fig. 
S4A). Total immune content was highly correlated with the amount of CD31+ vascular 
endothelium cells (Fig. 2C,D). However, there was no positive correlation between the 
number of immune cells or endothelial cells with the number of tumor cells, indicating no 
systematic differences between samples (Fig. S4B,C). These results highlight a dual role of 
Keren et al. Page 5
Cell. Author manuscript; available in PMC 2019 September 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
angiogenesis in tumor biology. While vasculature is essential for tumor growth and survival 
by providing nutrients, and is accordingly a therapeutic target (Weis and Cheresh, 2011), it is 
also associated with increased immune infiltration into the tumor.
To identify the immune populations within tumors we clustered the immune cells by 
canonical markers (Fig. 2E, S4D, Methods). We found that our analytical pipeline was able 
to accurately classify immune cells, even when those with opposing identifiers were located 
in close proximity to each other (Fig. 2F,H). The frequency of immune subsets across all 
patients identified populations with a high (e.g. macrophages, 25%) and low prevalence (e.g. 
NK cells, <1%) where B-cells (11%), CD4+ (15%); CD8+ (19%), and regulatory (1%) T 
cells fell in between (Fig. 2G). However, across patients, we found large differences in both 
the variety and composition of the immune cells (Fig. 2G, Fig. S4G). Interestingly, the 
composition of immune populations across patients was highly correlated with the total 
number of immune cells. For example, patients that have more immune cells tended to have 
a larger fraction of CD4+ T cells (Pearson R=0.87, P<10−12) and a smaller fraction of 
macrophages (Pearson R=0.71, P<10−6) (Fig. 2I,J. Fig. S4E shows absolute numbers). 
Assuming that the level of immune infiltration could serve as a surrogate for time, these 
results may suggest a structured ordering of subsets entering the tumor.
To further gauge ordering in immune infiltration we analyzed the co-occurrence of immune 
populations across patients. For each patient, we classified the different immune populations 
as either present or absent in the sample, and evaluated their co-occurrence usinga chi-
squared test. We found striking interdependence between the immune populations across 
patients (Fig. 2K). For example, all patients that had B cells also had CD4+ T cells and 
CD8+ T cells ( Χ2 P<0.005, P<0.0001 respectively). All patients that had NK cells, also had 
B cells (P<0.01). These results were robust to changing the thresholds for defining a 
population as present or absent (Fig. S4F). Similar correlations between one or two cell 
types have been observed previously (Yeong et al., 2017), but multiplexed imaging allowed 
us to evaluate the extent of this phenomenon across all major immune cell types 
simultaneously. Together, these results support a coordination in the immune response to 
tumors, whereby specific immune cells may be recruited to the tumor site in a context 
dependent manner.
Spatial analysis of TNBC reveals a hierarchy of organization of tumor and immune cells
To evaluate the spatial organization of the tumor-immune landscape in TNBC we developed 
a method for assessing spatial proximity enrichment for pairs of markers that accounts for 
differential tissue structure across varying cell numbers and composition (Fig. 3A). We 
quantified the number of positive cells for marker X that are located up to 100 pixels (39µm) 
from cells positive for marker Y. We repeatedly randomized the locations of Y+ cells, to 
generate a null-distribution of X-Y interactions and calculate a z-score representing the 
enrichment of X+ cells close or far from Y+ cells (Methods). Results were robust to ranging 
the distance and the number of randomizations (Fig. S5A). We applied this approach across 
the cohort and clustered the resulting pairwise-interactions. We found two types of 
prototypical spatial enrichment maps. In some patients, we observe a clear organization into 
two clusters – one encompassing tumor markers and the other encompassing immune 
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markers. This corresponds to a physical separation of predominantly-immune regions and 
predominantly-tumor regions (Fig. 3B left). Alternatively, other patients exhibited less 
structure, with no predominant clustering of tumor and immune markers, indicating 
increased mixing of tumor and immune cells (Fig. 3B right).
To quantify the degree of mixing between tumor and immune cells we devised a mixing 
score, defined as the number of immune-tumor interactions divided by the number of 
immune interactions (Fig. S5B). We identified three archetypical subtypes of tumor-immune 
interactions: Cold– with low immune infiltrate, Mixed – with high mixing between tumor 
and immune cells, and Compartmentalized – in which there are regions comprised 
predominantly of either immune or tumor cells. Notably, tumors with similar numbers of 
immune cells can differ in their spatial organization and degree of mixing (Fig. 3C).
While the aforementioned analysis can identify global organizational patterns within the 
tissue, the same global patterns may hinder the analysis when probing expression of specific 
proteins. For example, if a protein is primarily expressed by endothelial cells, its z-score will 
be highly influenced by the spatial enrichments of endothelial cells. To control for such 
biases, we repeated our spatial enrichment analysis in a context-dependent manner. The 
analysis was as described above with the additional constraint that when performing 
randomizations, the total number of positive cells for each category (immune, epithelial, 
mesenchymal and endothelial) must be preserved. Thus, the expression of a protein that was 
expressed by endothelial cells was randomized only within endothelial cells, such that the 
final z-score reflected the spatial enrichment of that particular protein, and not of endothelial 
cells (Fig. 3D, Methods).
Applying this analysis to all patients revealed multiple degrees of spatial organization (Fig. 
3E, S5C). First, we found enriched proximity of cells from the same lineage. For example, 
we identified tertiary lymphoid structures, comprised of clustered B cells (Fig. 3E,F,G1). 
Dendritic cells and neutrophils also tend to be spatially enriched next to cells of the same 
type (Fig. S5D). We also found that cells that were not necessarily from the same lineage, 
but shared similar expression features tended to be enriched in spatial proximity. For 
example, Ki-67+ tumor cells clustered together (Fig. 3E,F,G2) and IDO+ immune cells 
spatially clustered together, irrespective of their lineage (Fig. 3E,F,G3), which suggests that 
the functions associated with these proteins could largely be driven by the 
microenvironment. Finally, we identified enriched proximity of cells with distinct 
phenotypes. For example, patient 16 was enriched for neighboring cells expressing IDO and 
PD-1 (Fig. 3E,F,G4). Patient 6 had clusters of p53+ tumor cells, previously suggested to 
exert immunoregulatory activities (Di Minin et al., 2014), close to the tumor immune 
interface (Fig. 3H,I,S5E).
To identify spatial interactions that were either shared or unique between patients, we pooled 
the interactions from all patients together and performed hierarchical clustering (Fig. 3J, 
table S3). This showed that while some spatial features were represented with a subset of 
individuals (e.g. p53+ tumor cells near immune cells) others were more broadly conserved, 
suggesting design principles in tumor-immune organization (Fig. 3K). For example, we 
found conserved enrichment of neutrophils and depletion of B cells around tumor cells 
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across patients. Immune cells consistently exhibited perivascular localization. Interestingly, 
while immunoregulatory proteins were not expressed in all patients, when present they were 
enriched to be located in close proximity. Altogether, we find that TNBC tumors and their 
immune microenvironment are spatially structured, with multiple layers of organization 
conserved across individuals; highlighting the importance of spatial information for 
providing context to single cell expression data.
Enriched co-expression of immunoregulatory molecules by specific cell types and patients
To chart the landscape of immune suppression in TNBC, we targeted four 
immunomodulatory proteins, PD-1, PD-L1, IDO and LAG3 - all approved or currently 
undergoing clinical trials as immunotherapy targets (Andrews et al., 2017; Kwa and Adams, 
2018; Yu et al., 2017). We found that PD-1 and LAG3 were predominantly expressed by 
immune cells. In contrast, PD-L1 and IDO were expressed by both tumor and immune in 
similar proportions (Fig 4A). Examining the nature of immune cell types expressing each 
protein, we found that they can be expressed by a variety of cell types, consistent with some 
previous reports (Herbst et al., 2014) (Fig. 4B, S6A). For example, PD-L1 was expressed on 
CD4+ T cells, macrophages and dendritic cells. However, there was enrichment for specific 
cell types to express specific immunoregulatory proteins (Methods, Fig. 4C). PD-1 was 
enriched on both CD4+ and CD8+ T cells, whereas LAG3 was enriched on CD8+ T cells and 
Tregs, and PD-L1 and IDO were enriched on monocytes. The ability to easily distinguish 
differences in the expression of immunoregulatory proteins between cells types may provide 
a promising avenue for addressing inter-observer variability and discordance in PD-L1 
scoring (Troncone and Gridelli, 2017).
Beyond individual marker patterns, our multiplexed analysis revealed cells that expressed 
combinations of immunoregulatory proteins (Fig. 4D,E, S6B). For example, out of 2,532 
LAG3+ cells, 997 (39%) also expressed PD-1, in agreement with previous reports (Burugu et 
al., 2017; Woo et al., 2012). To assess the degree of co-expression, for each regulatory 
protein we compared the fraction of positive cells out of the general immune population, and 
the fraction of positive cells out of immune cells positive for each of the other regulatory 
molecules, and found consistently higher fractions for the latter (Fig. 4F). Specifically, we 
observed significant co-expression for IDO and PD-L1 (35%), and LAG3 and PD1 (39%). 
We confirmed the significance of these co-expressions even when controlling for enriched 
expression of different regulatory proteins by specific immune cell types (P<10−10, 
Methods, Fig. S6C). Interestingly, the relationship is not symmetrical (e.g. the proportion of 
LAG3+ cells out of PD-1+ cells is 0.15 and the proportion of PD-1+ cells out of LAG3+ cells 
is 0.39), which may suggest ordered or differentially-regulated protein expression. Certainly, 
these results indicate that expression of one immunoregulatory protein increased the 
probability that other regulatory proteins would be present. Recalling that immune cells 
positive for distinct immunoregulatory proteins were also enriched to reside in spatial 
proximity across patients (Fig. 3J–K) these combined observations reinforce that 
environmentally-derived signals may have pleiotropic effects in driving overall localization 
and coordination of immune inhibition.
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In line with quantifying the coincidence of immune cell populations within an individual 
tumor (Fig. 2J–K) we also capture the co-expression of immunoregulatory proteins across 
patients (Fig. 4G). We classified each immunoregulatory protein as either present or absent 
in an individual, and clustered the resulting matrix (Fig. 4G). We found that patients that 
express one immunosuppressive pathway are more likely to express another. Most patients 
had either no expression of immunoregulatory proteins, or they expressed several, with only 
5 patients expressing only a single regulatory protein. These results were robust to analysis 
of background probabilities, selection of thresholds, and to analysis of either absolute 
numbers or percentages (Fig. S6D–F). Expression of distinct immunoregulatory proteins 
was highly correlated; for example, all patients that had Tregs, also had expression of LAG3, 
PD-1, PD-L1 and IDO (Χ2 P<10−7, P=0.003, P=0.002, P<0.001 respectively). These 
observations may reflect the ability of IDO to drive the differentiation of naive CD4+ T cells 
toward an inducible Treg phenotype (Munn, 2011). Altogether, the landscape of immune 
regulation in this cohort suggest that combination immunotherapies would likely increase 
the total pool of targeted cells and could be synergistic in blockade of double positive cells 
in patients that respond to monotherapy, as demonstrated in both mice (Woo et al., 2012) and 
humans (Ott et al., 2017; Postow et al., 2015). However, due to the interdependence of 
immunoregulatory protein expression here, combination immunotherapies may provide only 
a modest increase to the pool of responsive patients, as observed in anti-PD-1 anti-CTLA-4 
combination therapies in melanoma (Larkin et al., 2015).
Expression patterns of immunoregulatory proteins coincide with TNBC architecture
We assessed inter-patient heterogeneity in immunoregulatory expression profiles. While we 
generally observed similar enrichments across patients (e.g. enrichment of PD-1 expression 
on T cells), we identified several pronounced differences between patients in the cell types 
expressing different regulatory proteins (Fig. S6G,H). We found that some patients have 
predominantly PD1+ CD4+ T-cells whereas others have predominantly PD1+ CD8+ T-cells. 
For example, patient 35 has 368 PD1+ immune cells. Of these, 68% are CD4+ and 8% are 
CD8+. Similarly, patient 14 has 390 PD1+ cells. However, of these, 7% are CD4+ and 78% 
are CD8+ (Fig. 5A). Expression of PD-1 on either Cytotoxic (CD8+) or T-helper cells 
(CD4+) may be crucial for tumor-immune interactions and immunotherapy outcome and is 
difficult to assess by current, IHC-based scoring criteria (Kwa and Adams, 2018).
Interestingly, we found that expression of immunoregulatory proteins by distinct cellular 
subtypes correlates with the spatial architecture of the tissue as mixed and 
compartmentalized (Fig. 3B–C). Predominance of PD1 expression by either CD4+ or CD8+ 
T-cells correlates with compartmentalized or mixed TNBC, respectively (Wilcoxon Rank 
Sum test P=0.022, Fig. 5A–C, Methods). This relationship was not driven by the ratio of 
total CD8+ and CD4+ T cells in compartmentalized and mixed tumors (Fig. S6I,J), nor was 
it affected by ranging the threshold used to include patients in the analysis between 10 and 
100 positive cells (Fig. S7A–C).
We observed similar architectural restrictions for PD-L1 and IDO. Here, individuals 
exhibited a wide range of enriched PD-L1 or IDO expression on tumor versus immune cells 
(Fig. 5D–F). At the same time, lineage enrichment of immunoregulatory proteins could be 
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linked to the tumor architecture where mixed tumors had PD-L1 and IDO expression 
primarily on tumor cells and compartmentalized tumors had PD-L1 and IDO expression 
predominantly on immune cells (Wilcoxon Rank Sum test, IDO P=0.002 , PD-L1 P<10−4). 
These results relate molecular expression profiles in a cell-specific manner to histological 
attributes of tumors, highlighting the multiple layers of information that can be gleaned from 
multiplexed imaging.
The tumor border has complex multicellular structures of immune regulation
To further explore the relationship between molecular expression and tissue architecture, we 
focused on the tumor-immune boundary, which has been previously implicated to play a 
prognostic role in tumor progression (Fortis et al., 2017). We developed a computational 
approach to automatically identify the tumor-immune border from the clustering annotations 
of the cells, and applied it to the compartmentalized tumors (Methods). Using a threshold of 
100 pixels (39μm), for each tumor we classified the tumor and immune cells as those that 
resided close or far from the border (Fig. 6A). To identify differential expression along the 
border, for each marker in every patient we extracted the expression distribution on cells 
close and far from the border and compared the distributions using Wilcoxon’s Rank Sum 
test. For example, in patients 4 and 9 we found a gradient of histone H3 methylation to 
acetylation levels on tumor cells perpendicular to the tumor-immune border (Fig. 6B (white 
arrows), C, Wilcoxon P=10−20). Since H3K9ac was shown to be correlated with open 
chromatin and H3K27me3 with closed chromatin (Kouzarides, 2007), these global changes 
in their ratios may indicate that cells on the tumor border are more transcriptionally active 
than those in the tumor center.
To more broadly assess recurrent spatial expression within compartmentalized TNBC 
patients, we combined significant results (Bonferroni corrected, P<10−5) across patients and 
markers and subjected the resulting data to hierarchical clustering (Fig. 6D) and principal 
component analysis (PCA, Fig. 6E). In accordance with our previous results, we found that 
B cells are consistently depleted along the tumor boundary across patients (Fig. 6D, 3J). In 
addition, we identify a subset of patients, which exhibit unique properties along the border 
(patients 4,5,9,10 and 40). This cluster of patients displayed increased expression of PD-L1, 
PD-1, and IDO by CD11c+ CD11b+ immune cells, a phenotype suggestive of myeloid 
derived suppressor cells (Gabrilovich and Nagaraj, 2009). These patients also tended to have 
HLA-DR positive tumors, with higher expression close to the boundary (Fig. 6F). This 
expression pattern may be suggestive of localized production of cytokines like IFN-γ 
(Carrel et al., 1985). These findings indicate that the tumor-immune border is a unique site 
of immune inhibition with altered expression profiles by both tumor and immune cells. The 
shared expression profiles for multiple proteins in distinct patients suggest a prototypical 
spatial expression signature, which may stratify patients with similar tumor-immune 
interactions (Fig. 7A).
Finally, we examined whether the tumor-immune landscape is relevant to prognosis. We 
partitioned the patients into ‘Cold’, ‘Compartmentalized’ and ‘Mixed’ as described above. 
Since the ‘Cold’ group had only 5 patients, we discarded it from further analysis. 
Compartmentalized organization was associated with increased survival (Cox regression 
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HR=4.97, P=0.03 Fig. 7B), regardless of the specific threshold used to separate 
compartmentalized and mixed phenotypes, and independently from pathological TIL scoring 
(Fig. S7D–H). This suggests that the clinical outcome of TNBC is influenced by the tumor 
immune microenvironment and emphasizes the clinical importance of the immune system 
even in non-immunotherapeutic settings.
Discussion
We developed MIBI-TOF, a multiplexed imaging platform, and applied it to interrogate the 
tumor-immune landscape by simultaneously imaging the expression of 36 proteins in 
archival tissues of 41 patients. This approach allowed us to describe how cell identity and 
phenotype (who) is related to tissue architechure (where) in TNBC. We found that the 
tumor-immune microenvironment can be categorized into prototypical archetypes with 
structured cellular composition, spatial arrangement, and expression of regulatory proteins 
that related to overall survival. Interrelated presence of distinct immune cell populations in 
the tumor region sheds light on how different immune cells come together and operate as a 
system to mount the immune response, and the co-dependence between different cell types. 
The connection observed between the presence of immune subsets and infiltrate size (Fig. 2) 
may suggest temporal ordering in immune infiltration into the tumors. Temporal ordering of 
the immune response has been shown in various processes, including viral infections (Dunn 
et al., 2009) and inflammation (Bagaitkar, 2014), and may play a role here. Further 
investigations, including longitudinal data, are necessary to further delineate ordering and 
immune cell co-dependence in cancer.
We also identified conserved design principles in the relative spatial organization of tumor 
and immune cells (Fig. 3). These included enriched proximity of cells from the same 
lineage, as well as cells from distinct lineages with similar phenotypes (e.g. proliferating 
cancer cells or checkpoint-positive immune cells) and specific distinct phenotypes (e.g. cells 
positive for different immunoregulatory proteins). These implicate a prominent role of the 
microenvironment in driving cell phenotype, cell recruitment, or both (Oelkrug and Ramage, 
2014). In this sense, multiplexed imaging is uniquely positioned to decouple 
microenvironmental effects from cell-intrinsic properties.
Given the recent successes of checkpoint blockade in establishing durable remissions in 
multiple malignancies (Ribas and Wolchok, 2018), we evaluated the expression of 
immunoregulatory proteins across patients (Fig. 4). We found that expression of one protein 
increased the probability that other regulatory proteins would be present, both at the cellular 
level and at the patient level. In conjunction with the enriched spatial proximity of distinct 
regulatory proteins, these results support overlapping microenvironmental cues in inducing 
immune inhibition. These mechanisms could include shared signaling pathways and positive 
feedback between immunoregulatory proteins (Nirschl and Drake, 2013; Woo et al., 2012), 
and may be a valuable avenue for future mechanistic exploration.
Expression of immunoregulatory proteins differed across patients not only in quantity, but 
also with respect to the identity of the cell types expressing them. For example, PD-L1 was 
primarily expressed by tumor cells in some patients and by immune cells in others (Fig. 5). 
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Importantly, these distinctions represent different tumor-immune states, which are currently 
not captured in patient stratification to clinical trials. Interestingly, these patterns of 
expression coincided with the tumor-immune architecture in patients as Cold, Mixed and 
Compartmentalized. Thus, the observations here allow us to relate single cell expression 
patterns to broader histological attributes of the tumors. This relationship was especially 
striking in a subset of compartmentalized patients, which exhibited ordered expression 
patterns by both immune and tumor cells at the tumor-immune border (Fig. 6). These 
included increased expression of PD-L1 and IDO by monocytes and increased expression of 
HLA-DR and H3K9ac by the tumor cells at the boundary. We note that the distinction 
between compartmentalized and mixed is not clear cut, as we observe a continuum of 
mixing scores between tumor and immune cells across patients. Since the 
compartmentalized histology correlated with improved overall survival, we propose that 
further interrogation into additional patients displaying similar expression properties will 
prove valuable in the context of standard-of-care chemotherapy and emerging 
immunotherapy regimens. Linking these micro-environmental immune features to existing 
molecular data on TNBC (Burstein et al., 2015; Lehmann et al., 2016) may provide future 
avenues for patient stratification and therapeutic design. Emerging cohorts, in which several 
regions are profiled for each patient, are needed to investigate the intra-patient heterogeneity 
in the composition and architecture of the tumor-immune microenvironment and its 
relationship to the molecular attributes of the tumor.
We developed a multi-step pipeline to analyze MIBI-TOF data, including low-level data 
processing, segmentation, extraction of counts, clustering, and spatial analysis. Each of these 
steps could be algorithmically improved, and we anticipate this to be an active field of 
research in the near future. We note that applying deep learning for nuclear segmentation 
outperformed all other methods in both segmentation results, scalability, and ease of use. 
Follow-up work which fully exploits the power of MIBI-TOF, such as extending this method 
to include additional cellular compartments as well as multi-cellular structures and 3-D data, 
will facilitate quantification of finer attributes of protein expression and regulation. Our 
spatial analysis revealed multiple layers of organization within tumors. This hierarchical 
spatial organization poses a confounding factor when evaluating proximity enrichment and 
may lead to misleading results if not properly controlled.
Taken together, our application of MIBI-TOF has revealed how tumor expression and 
immune composition are interrelated within a histological context that correlates with 
overall survival in TNBC. A better understanding of the spectrum and dynamics of immune 
states in cancer is critical for establishing faithful models and advancing therapeutic 
strategies that address the complexity of this disease. As clinical trials of immunotherapeutic 
agents and their various combinations progress, this approach should provide the insights 
needed to develop reliable guidelines for drug selection that will increase therapeutic 
response.
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STAR Methods
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Michael Angelo (mangelo0@stanford.edu).
Experimental model and subject details
Samples of TNBC patients of no special type (ER and PR positivity less than 1%, HER2 
unamplified and Her2 not 3), as well as tonsil, lymph node, placenta, gastrointestinal tract 
and breast carcinoma controls were obtained from Stanford Pathology department. TNBC 
biopsies were reviewed by expert pathologists and representative 1mm cores were compiled 
into a tissue microarray (TMA). For one of the patients two cores were included in the 
dataset (#15 and #22). H&E staining was performed on all cores as previously described. 
For patients 1–14, an additional core was used for H&E staining, to assess the intra-patient 
variability in the amount of immune infiltration (Fig. S3). TIL scores were generated by a 
pathologist using H&E stained sections of the tissue microarray cores, according to 
recommended guidelines (Salgado et al., 2015). A four-tier scoring system was used such 
that TIL score 1, 2, 3, and 4 corresponded to TIL cellularity of <25%, 25–49%, 50–75%, 
and >75%, respectively. Data regarding age, tumor grade, TNM, clinical stage, TIL 
enumeration and survival for all patients are provided in table S2.
Method details
Gold Slide preparation
Slide preparation was performed at the Stanford Nano Shared Facility (SNSF). Superfrost 
plus glass slides (Electron Microscopy Sciences, Hatfield, PA) were soaked in water with 
dish detergent and rinsed extensively with distilled water and then acetone (Avantor-Macron 
Fine Chemicals, Center Valley, PA). Acetone was immediately evaporated under a stream of 
air to avoid trace of residues. Slides were coated with Tantalum (Ta, 30nm) and Gold (Au, 
100nm). The slides were placed ten at a time in adjustable rails in an e-beam evaporation 
station and pumped down for about two hours prior to deposition. The base pressure before 
the deposition was ~4 × 10−7 Torr. The distance between the source and the substrate was 
30cm.The Ta was evaporated at a rate of ~10 Angstroms per second. The Au was evaporated 
immediately after at a rate of 10–15 Angstroms per second. Gold-coated slides were 
silanized in acetone with 3-aminopropyltriethoxysilane for 30 min then washed with acetone 
and air dried (Vactabond, Burlingame, CA). Slide were baked at 70°C for 30 min and kept 
dry at room temperature until use.
Antibody conjugation
A summary of antibodies, reporter isotopes, and concentrations can be found in Table S1. 
Metal conjugated primary antibodies were prepared as described previously (Bendall et al., 
2011). Following labeling, antibodies were diluted in Candor PBS Antibody Stabilization 
solution (Candor Bioscience GmbH, Wangen, Germany) to 0.2 mg mL−1 and stored long-
term at 4 °C.
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Staining
Tissue sections (4 μm thick) were cut from FFPE tissue blocks of the TNBC tissue 
microarray (TMA) or control tissues using a microtome, mounted on silanized-gold slides 
for MIBI-TOF analysis. Slide-tissue sections were baked at 70°C for 20 min. Tissue sections 
were deparaffinized with 3 washes of fresh-xylene. Tissue sections were then rehydrated 
with successive washes of ethanol 100% (2×), 95% (2×), 80% (1×), 70% (1×), and distilled 
water. Washes were performed using a Leica ST4020 Linear Stainer (Leica Biosystems, 
Wetzlar, Germany) programmed to 3 dips per wash for 30 sec each. The sections were then 
immersed in epitope retrieval buffer (Target Retrieval Solution, pH 9, DAKO Agilent, Santa 
Clara, CA) and incubated at 97°C for 40 min and cooled down to 65˚C using Lab vision PT 
module (Thermofisher Scientific, Waltham, MA). Slides were washed with a wash buffer 
made with PBS IHC Tween buffer (Cell Marque, Rocklin, CA) containing 0.1% (w/v) BSA 
(Thermofisher Scientific, Waltham, MA). Endogenous avidin, biotin binding proteins were 
blocked using Avidin/Biotin blocking systems (Biolegend, San Diego, CA). Sections were 
treated successively with avidin and biotin blocking solutions for 10 min and washed for 5 
min in wash buffer. Sections were then blocked for 1h with 3% (v/v) donkey serum (Sigma-
Aldrich, St Louis, MO) diluted in TBS IHC wash buffer (Cell Marque, Rocklin, CA). Metal-
conjugated antibody mix was prepared in 3% (v/v) donkey serum TBS IHC wash buffer and 
filtered using centrifugal filter, 0.1 μm PVDF membrane (Ultrafree-MC, Merck Millipore, 
Tullagreen Carrigtowhill, Ireland). Two panels of antibody mix were prepared where the first 
panel contained the majority of the metal-conjugated antibodies and a biotinylated anti-PD- 
L1 antibody. This antibody mix was incubated overnight at 4°C in humid chamber. The 
second mix contained antibodies of structural genes with strong signal and an anti-biotin 
antibody. After overnight incubation, slides were washed on orbital shaker for 5 min in wash 
buffer (Table S1). The second, antibody mix was then applied and incubated for 1h at 4°C. 
Slides were then washed twice 5 min in wash buffer and fixed for 5 min in diluted 
glutaraldehyde solution 2% (Electron Microscopy Sciences, Hatfield, PA) in PBS-low 
barium. Slides were then rinsed briefly in PBS-low barium. Tissue sections were then 
dehydrated with successive washes of Tris 0.1 M (pH 8.5), (3×), distilled water (2×), and 
ethanol 70% (1×), 80%(1×), 95% (2×), 100% (2×). Slides were immediately dried in a 
vacuum chamber for at least 1 h prior to imaging.
IHC
The protocol for IHC closely followed the MIBI-TOF staining protocol, with a few changes. 
Before blocking, endogenous peroxidase activity was quenched by incubation in 3% H2O2 
for 30 min and sections were washed with H2O on orbital shaker for 5 min. Sections were 
stained using the ImmPRESS universal (Anti-Mouse/Anti-Rabbit) kit (Vector labs) 
according to the manufacturer’s guidelines.
Tissue controls and titer selection
For each antibody, appropriate positive and negative tissue controls were selected. Tissues 
included tonsil, lymph node, placenta, gastrointestinal tract, skin, breast and breast 
carcinoma. The antibody panel was mixed according to the manufacturers’ suggested titers 
and then serially diluted 2-fold five times. For each antibody, the working titer was 
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determined as the titer that yielded maximal separation between signal and noise across 
tissues (See section ‘Noise Removal’ for a description of how signal and noise were 
separated).
MIBI-TOF
Quantitative imaging was performed using a custom designed MIBI-TOF mass spectrometer 
equipped with a duoplasmatron ion source. O2+ primary ions are focused onto the sample at 
a working distance of 15 mm and 45° incident angle using a two lens, 30KV ion column 
operating in crossover mode. For each pixel in the image, corresponding positions on the 
tissue are sequentially sputtered with the primary ion beam using a fly back raster pattern. 
Secondary ions collected using a +68V sample bias and −125V extraction field subsequently 
pass through an electrostatic analyzer (ESA) with 5eV energy acceptance that has been 
tuned for preferential transmission of monoatomic ions relative to polyatomic organic 
species.The secondary ions then enter an orthogonal time of flight mass spectrometer with a 
mass range of 1–200 m/z+ and mass resolution of 1000 m/Δm operating at 100KHz 
repetition rate.Ion events are recorded using a time to digital converter (TDC) with 500ps 
time resolution.Lastly, multiple TOF spectra for each pixel are summed and saved to a data 
file.The experimental parameters used in acquiring all imaging data are as follows:
• Pixel dwell time:6.4ms
• Image size:800um2 at 2048 × 2048 pixels (for cohort data) or 400um2 at 
1024×1024 pixels (for controls).
• Probe size:500nm
• Primary ion current:3.5 nA O2+
• Ion dose per unit area:147 pC/μm2
Primary ion current was monitored continuously via an in stage current monitor, which 
demonstrated maximal variations of approximately +/− 1% during continuous operation over 
a 24 hour period.Using the acquisition settings aforementioned, this cohort of 41 TNBC 
patients was acquired across 13 days of continuous operation using autonomous software-
based acquisition from pre-defined user FOVs.A total of ~180 million pixels were acquired 
in that time, generating a total of 1763 images.
Quantification and statistical analysis
Image analysis pipeline
Spectra calibration and file conversion.—For each field of view, Mass-spec pixel data 
was converted to a multi-dimensional TIFF. Counts for each mass were defined according to 
whether they fell between the ‘Start’ and ‘Stop’ values defined in table S1. For example, for 
FoxP3, conjugated to Pr 141, masses between 140.8 and 141.2 were considered. Time of 
Flight data was calibrated using the Sodium (Na, mass 22.99) and Gold (Au, mass 196.97) 
peaks (Fig. S2A).
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Background subtraction.—Background across all channels was highly correlated to 
bare spots (with no tissue) on the slide. Background was filtered using a blank channel (mass 
128–132). The background image was smoothed using a Gaussian kernel with R=3 pixels 
and then thresholded (T=0.07) to obtain a binary mask. For all other channels, positive 
pixels in the background channel were subtracted by two counts. Following the subtraction, 
negative values were converted to zeros. We found that this removal was sufficient to remove 
background-related noise, while preserving real signal. Channel 169 (CD45) exhibited 
additional background signal, highly correlated with gold, and so for all fields of view, this 
channel underwent similar background removal using the gold channel (T=0.3). Channel 
144 (CD16) displayed non-specific nuclear signal, and underwent similar background 
removal using channel 89 (dsDNA) (T=0.2) (Fig. S2B).
Necrosis.—Necrotic regions were automatically identified using the dsDNA channel and 
verified using pathological inspection of H&E serial sections. The dsDNA image was 
smoothed using a Gaussian kernel with R=2, and subjected to morphological closing and 
opening (matlab imclose, imopen), and connected components of size < 10,000 pixels were 
removed. Necrotic regions were removed from the channels used for segmentation prior to 
segmentation (Fig. S2C).
Batch Normalization.—Quantile normalization was performed for Pan-keratin in patients 
1–29 and 31–41, which were stained individually and exhibit systematic differences in 
intensity. Counts for each pixel in each batch were sorted and subsampled to create equally 
sized samples between the two batches. A transfer function mapped each value in batch 2 to 
the correspondingly ranked value in batch 1 (Fig. S2D).
Noise Removal.—MIBI-TOF data has two properties, which make it a unique challenge 
for denoising: (1) Low intensity values. Pixel intensity values vary between antigens and 
elements and can range from hundreds (e.g. for Au coming from the slide) to single counts 
for low abundant antigens. (2) For low abundant antigens, signal is sparse and pixelated. 
Therefore, there is more information about positive signal in the density of positive pixels, 
rather than their intensity. To filter noise by signal density a k-nearest-neighbor approach 
was used. Each count was given a density-determined confidence score, by calculating the 
average distance to the 25 nearest positive counts. Pixels with counts larger than one were 
treated as several counts with distance 0 from each other. Removal thresholds were 
determined as the crossing points in the bimodal distributions and low-confidence counts 
were removed. Removal thresholds for each channel are specified in table S1. Patient 30 had 
particularly noisy data and was therefore removed from all further analysis (Fig. S2E).
Aggregates removal.—In addition to the real staining, some channels exhibited dense, 
localized staining, which appeared like ‘antibody aggregates’. To remove aggregates, 
denoised images were smoothed using a Gaussian kernel with R=1 and the resulting image 
was binarized using Otsu’s method. Pixels of small connected components were set to zero. 
Size thresholds for each channel are specified in Table S1 (Fig. S2F).
Image segmentation.—Nuclear segmentation was performed by adapting DeepCell (Van 
Valen et al., 2016), a CNN-based approach for single-cell image segmentation to MIBI-TOF 
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data. Generating training data. To generate training data, the channels of dsDNA, 
H3K27me3 and H3K9ac were summed, to generate a strong and robust nuclear image. 
Color overlays of the nuclear channel (blue), an immune membrane channel (CD45 and 
HLA-DR, green), and a cancer membrane/cytosol channel (Pan-Keratin and Beta-catenin, 
red) were also used to guide the manual segmentation in ambiguous cases. The nuclear 
images of patients 1 and 2 were manually segmented in ImageJ (Schneider et al., 2012) 
using a Wacom Intuos Draw graphics tablet as previously described (Van Valen et al., 2016). 
For each patient, three binary label images were generated, marking pixels classified as 
either nuclear interiors, nuclear borders or background. Edges were augmented by a radial 
dilation with R=1 to increase their prevalence. Training data was generated for the images of 
dsDNA, H3K27me3 and H3K9ac. Patches of 61×1×3 pixels around each annotated pixel 
were taken for 106 pixels, randomly sampled to maintain equal representation of the three 
labels. Training images were normalized by subtracting a 61×61 averaging filter and 
dividing by the std of the whole image. Training images were augmented by a random 
rotation of 0 to 180 degrees and reflection about the vertical and horizontal axes. Training 
the network. The architecture of the network was previously described (Van Valen et al., 
2016). The data was split into training (90%) and test (10%). For training, the batch size was 
set to 256 and ran for 5 epochs. The learning rate was set to 0.01, the decay to 0.95 and the 
Nesterov momentum to 0.9. Segmenting new images. The trained network was run on the 
images of all patients in the cohort. The images were normalized in the same fashion as the 
training images. Post processing. The probability map for the ‘nuclear interior’ was 
thresholded using Otsu’s method to define nuclei borders. Regional maxima were identified 
(matlab imextendedmax, H=0.1) and adjacent nuclei were separated by watershedding 
(Meyer, 1994). Small nuclei (<40 pixels) were fused to adjacent nuclei. Cell Borders were 
defined as a 3-pixel radial expansion around the nuclei.
Expression assignment.—For each cell, for each maker, the total intensity per cell was 
computed. Values were divided by the cell size, Arcsinh transformed, and standardized 
across markers using std normalization.
Clustering.—Cells with low expression across all markers used for clustering (sum < 0.1) 
were removed prior to clustering. Cells from all patients were clustered in a hierarchical 
scheme. Initially, cells were clustered into ‘Immune’ and ‘Non-immune using 16 markers 
(CD45, FoxP3, CD4, CD8, CD3, CD20, CD16, CD68, MPO, HLA-DR, Pan-Keratin, 
Keratin17, Keratin6, p53, Beta catenin, EGFR). FlowSOM (Van Gassen et al., 2015) was 
used to cluster the data into 100 clusters, and then similar clusters (cosine distance < 0.05) 
were merged by hierarchical clustering. The same approach was used to cluster Non-
immune cells into Epithelial, Mesenchymal, Endothelial and Unidentified using 8 channels 
(Vimentin, SMA, CD31, Beta-catenin, EGFR, Keratin 17, Keratin 6, Pan-keratin). Immune 
cells were clustered into 12 groups (Fig. 2E) using 13 channels (CD4, CD16, CD56, CD209, 
CD11c, CD68, CD8, CD3, CD20, HLA-DR, CD11b, MPO and FoxP3). The clustering 
scheme is illustrated in Fig. S2I.
Co-occurrence of immune populations.—Immune categories were truncated to those 
that were clearly defined (CD4 T, CD8 T, NK, B, Macrophages), and for each patient the 
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number of immune cells in each category was extracted. A threshold of 30 cells was used to 
decide whether an immune population was present or absent in a patient. Changing the 
threshold up to 130 cells did not have a significant effect on the results (Fig. S4F). 
Significance of co-occurrence was assessed using a Χ2 test.
Spatial analysis.—Cells were considered positive for a protein if their scaled expression 
level was >0.5. For each cell, the physical distance to all other cells in the core was 
calculated and stored as an interaction matrix. For each pairwise combination of proteins (X 
and Y), the distance matrix was truncated to include only interactions between X-positive 
and Y-positive cells. Interactions with distance smaller than 100 pixels (39µm) were counted 
as close. To evaluate whether the number of close interactions is significant given the total 
number of cells in the tissue, the tissue architecture and the number of cells positive for X 
and Y, a bootstrap approach was used. The location of Y-positive cells was randomized, 
while keeping their overall number constant and the number of close interactions was 
quantified as described above. This process was repeated 500 times to generate a null 
distribution, and a z-score was calculated to assess the deviation of the actual number from 
the null distribution. Results were robust to ranging the distance between 100 and 500 
pixels, and increasing the number of randomizations to 500 (Fig. S5A). Importantly, the 
approach yields different values when calculating the spatial enrichment of protein X close 
to protein Y, and when calculating the spatial enrichment of protein Y close to protein X. A 
context-dependent spatial enrichment analysis was used to control for the hierarchical 
organization of the tissue. The analysis was as described above with the additional constraint 
that when performing randomizations, the total number of Y-positive cells for each category 
(Immune, Epithelial, Mesenchymal and Endothelial) must be preserved. Pairwise interaction 
z-scores for all patients are provided in table S3.
Tumor-Immune mixing.—A mixing score was developed to quantify the degree of 
mixing between tumor and immune cells. The neighbors of each cell were defined as cells 
with direct contact with the cell of interest and were identified using Haralick’s gray-level 
co-occurrence matrix (Haralick et al., 1973). The mixing score for a patient was defined as 
the proportion of immune cells touching tumor cells and was formally calculated as the 
number of immune- tumor interactions divided by the number of immune-immune 
interactions in the neighbors’ matrix. Patients with less than 250 immune cells (N=6) were 
defined as ‘Cold’. Patients with a mixing score < 0.22 (N=15) were defined as 
compartmentalized and the rest of the patients (N=20) were defined as Mixed. The threshold 
was chosen to minimize the intra-group variability and maximize the inter-group variability. 
All results were robust to the specific selection of the threshold, as demonstrated in figure 
6K for the survival analysis. The relationship between the mixing score and the number of 
immune cells in the sample as quantified both by MIBI-TOF and by pathological TIL 
analysis is shown in figure S7E–H.
Analysis of immunoregulatory protein expression.—To assess the significance of 
co-expression, for each pair of immunoregulatory proteins X and Y, the background 
probability for an immune cell to express protein X, P(X) was calculated and compared to 
P(X|Y), the conditional probability of expressing X given expression of Y. Significance of 
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co-occurrence was assessed using a Χ2 test. A bootstrapping approach was used to further 
validate that pairs of immunoregulatory proteins were enriched for co-expression when 
controlling for enriched expression of different regulatory proteins by specific immune cell 
types. For each pair of proteins, X and Y, the number of double-positive cells was quantified. 
The identity of Y-positive cells was randomized while preserving the total number of 
positive cells within each immune category, and the number of X-Y-double-positive cells 
was quantified. Randomizations were repeated 500 times to generate a null distribution, and 
a z-score was calculated to assess the deviation of the actual number from the null 
distribution (Fig. S6C,D).
To examine co-occurrence of expression of immunoregulatory proteins across patients, for 
each patient the number of positive cells for each regulatory protein was extracted. A 
threshold of 30 positive cells was used to decide whether a protein was expressed or not in a 
patient. Ranging the threshold from 20 to 50 cells did not have a significant effect on the 
results (Fig. S6E). The analysis was repeated, thresholding according to the fraction of 
positive cells, rather than their absolute number. Ranging the threshold between 1%−4% did 
not have a significant effect on the results (Fig. S6F). Significance of co-occurrence was 
assessed using a Χ2 test.
Analysis of the tumor-immune border.—Analysis of the tumor-immune border was 
restricted to compartmentalized tumors (see above). Identification of the tumor-immune 
boundary. To identify the border, two binary images were generated, marking immune and 
tumor cells. Both images were dilated using a squared structuring element of size 10 pixels, 
to generate large connected components. Overlaps between tumor and immune signal 
resulting from the dilation were set to zero. Connected components of both immune and 
tumor signal were identified (Matlab bwconncomp) and connected components of size < 
5000 were removed. Images were closed using a disc-shaped structuring element with a 
radius of 10 pixels to smoothen the edges. Holes were removed by inverting the images and 
removing connected component of size < 10000 pixels. Edges of immune and tumor areas 
were identified (Matlab edge) and the edges on the border of the image were removed. 
Edges identified by both tumor and immune images were classified as the tumor-immune 
border. For each cell, it’s distance to the boundary was defined as the shortest distance from 
the center of the cell to one of the boundary pixels (Matlab knnsearch). Cells were defined 
as either close (distance < 100 pixels), far (distance > 100 pixels) or Infiltrating (immune 
cells in tumor side of the boundary or tumor cells in immune side of the boundary). Analysis 
of protein expression close/far from border. This analysis was performed for every 
compartmentalized patient, for tumor and immune cells separately. For each protein, the 
expression distribution of cells close to the boundary was compared with the expression 
distribution of cells far from the boundary. Proteins for which there were less than 50 
positive cells overall (expression < 0.5) were discarded from the analysis. The distributions 
were compared using Wilcoxon’s Rank-Sum test. A Bonferroni- corrected p-value of 0.05 
was used to define significant changes. H-values were modified such that H=1 represents an 
interaction that is enriched close to the border and H=−1 represents an interaction that is 
enriched far from the border. H-values for tumor and immune cells were combined and 
subjected to hierarchical clustering and principle component analysis (PCA).
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Survival Analysis.—De-identified data on tumor size, tumor grade, recurrence, date of 
diagnosis, and date of death was obtained from Stanford hospital. Association between 
tumor type and survival was evaluated using univariate Cox regression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Multiplexed Imaging of subcellular expression of 36 proteins in 41 TNBC 
patients
• Enriched co-occurrence of immune populations define a structured immune 
environment
• Mixing of tumor and immune cells varies from Compartmentalized to Mixed 
patients
• Expression of PD-1 and PD-L1 by distinct cells relate to tumor histology and 
survival
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Figure 1: Development of a multiplexed imaging assay for the tumor-immune microenvironment
(A) Experimental workflow for MIBI-TOF. Clinical tissue specimens are stained using a 
mixture of antibodies labeled with elemental mass tags. The samples are rasterized by a 
primary ion beam that releases lanthanide adducts of the bound antibodies as secondary 
ions, which are recorded by a TOFMS. This results in an n-dimensional image depicting 
protein expression in the field. (B) MIBI-TOF images of samples stained with the panel in 
(A). (C) Serial sections of lymph node were stained with three sub-panels, each including 30 
out of the 36 antibodies. Bottom: integrated counts across the image as a function of mass 
for the three panels. (D-H) Assay validation: Color overlays of tonsil show expected patterns 
of histologic architecture, subcellular staining (membrane/nucleus), and protein co-
expression. (I) MIBI-TOF images of four TNBC patients.
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Figure 2: Automated image analysis pipeline delineates ordered immune composition in TNBC
(A) Analytical pipeline for multiplexed imaging data. Cell segmentation is performed using 
a pixel-based convolutional neural network. Following segmentation, cellular features are 
extracted and cells are clustered into distinct populations. (B) The number of immune cells 
per patient. (C) The number of immune cells is correlated with the number of endothelial 
cells across patients. (D) Staining for tumor (Pan-Keratin), immune (CD45) and 
endothelium (CD31) in two patients. (E) Immune cells clustered by protein expression. 
Expression values for each protein are scaled from zero to one. (F) Pseudo-coloring of 
patient 12. Immune cells are color-coded as in E. Other cell types are colored gray. (G) 
Immune composition in all patients, and specific patients, color-coded as in E. (H) 
Expression of seven markers in the region shown in F. (I) Pseudo-coloring of three patients, 
color-coded as in E. (J) Left: Patients, sorted by number of immune cells (gray bars). Right: 
Immune composition normalized from zero to one (x-axis) in all patients (y-axis). 
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Percentage of CD4+ T cells (magenta) increases whereas percentage of macrophages (green) 
decreases with total immune number. (K) For five immune populations shown is their 
presence or absence across patients.
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Figure 3: Spatial analysis reveals a hierarchy of organization of tumor and immune cells
(A) Assessment of enriched proximity/distance between two cell types, red and green. 
Location of red cells is randomized to generate a null distribution of red-green interactions. 
The actual number is compared to the distribution to calculate a z-score. (B) Top: Heat maps 
depicting spatial enrichment z-scores between pairs of proteins. Orange and blue boxes mark 
immune-and tumor-related proteins, respectively. Bottom: Pseudo coloring of immune and 
tumor cells. (C) Left: Patients, sorted by the number of immune cells and colored by their 
spatial architecture. Right: Pseudo coloring of immune and tumor cells in three patients. (D) 
Context-dependent spatial enrichment (CDSE) analysis controls for hierarchical tissue 
organization. The location of red cells is randomized only within the tumor compartment. 
(E) Heatmap of CDSE z-scores between pairs of proteins in patient 16. Squares are 
highlighted in F and G. (F) Pseudo-coloring of cell populations highlighted in E and G. (G) 
Protein staining in boxed regions in F. (H) Heatmap of CDSE z-scores between pairs of 
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proteins in patient 6. Zoom-in on p53 shows its proximity to immune cells. (I) Pseudo-
coloring of patient 6 showing increased proximity of p53+ tumor cells to immune cells. (J) 
CDSE z-scores, grouped for all patients. Patients are ordered as in K. (K) Zoom-in on a few 
interactions in J displaying variability (CD45xp53), depletion (Pan-KeratinxCD20) or 
enrichment (rest) across patients. Gray denotes patients with less than 10 positive cells for 
either maker.
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Figure 4: Enriched co-expression of immunoregulatory proteins by cell types and patients
(A) Fraction of immune and tumor cells expressing immunoregulatory proteins (IRPs). 
Mean and SE across patients are shown. (B) Color overlays of immune lineage proteins 
(rainbow) and IRPs (white). (C) For each IRP, shown is the log2 fold change relative to the 
baseline in representation of the different immune populations. (D) Cellular co-expression of 
IRPs. (E) Co-expression of IRPs. (F) For each IRP, shown is the fraction of positive cells out 
of all immune cells, and out of immune cells positive for other IRPs. Left bar is consistently 
the lowest, indicating increased probability for IRP co-expression. (G) Presence or absence 
of IRPs and Tregs across patients.
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Figure 5: Expression patterns of immunoregulatory proteins coincide with TNBC architecture
(A) PD-1+ immune cell composition in two patients. Immune populations are color-coded as 
in 2E. (B) For all patients with over 20 PD-1+ cells (x-axis) shown is the log ratio of 
PD-1+CD8+ and PD-1+CD4+ T-cells. Patients are colored by their spatial architectures. 
Mixed tumors tend to have more PD-1+CD8+ T cells than PD-1+CD4+ T cells, as 
determined by Wilcoxon rank-sum test. (C) Color overlay of CD8, CD4 and PD-1. (D) PD-
L1+ cell composition in two patients. (E) Same as B, showing the log ratio of PD-L1+ tumor 
and immune cells. (F) Color overlay of CD45 (immune), Pan-keratin (tumor) and PD-L1. 
(G) IDO+ cell composition in two patients. (H) Same as B, showing the log ratio of IDO+ 
tumor and immune cells. (I) Color overlay of CD45 (immune), Pan- keratin (tumor) and 
IDO.
Keren et al. Page 31
Cell. Author manuscript; available in PMC 2019 September 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6: The tumor border has complex multicellular structures of immune regulation
(A) Computationally-derived tumor-immune border (white line) in patients 4 and 9. Tumor 
and immune cells are pseudo-colored by their location relative to the border. Insets are 
shown in F. (B) Color overlays for H3K9ac and H3K27me3. The tumor-immune border is 
white. Arrows show a gradient of HH3 acetylation to methylation in tumor cells from the 
boundary inwards. (C) Distribution of the log-ratio of H3K27me3 to H3K9ac in tumor cells 
close or far from the tumor- immune border. Median is marked in red. (D) For each protein 
in either tumor (blue) or immune (orange) cells (x-axis), shown is the H-value from a 
Wilcoxon rank-sum test evaluating differential expression in cells close or far from the 
border for compartmentalized patients (y- axis). Patients and proteins are sorted by 
hierarchical clustering. Colored rectangles show groups identified by clustering and 
principle component analysis (PCA). Black box highlights results in C. (E) PCA of the data 
in D. Patients are plotted on the first and second PCs. (F) Staining for different proteins in 
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the boxed regions in A. The tumor-immune boundary is in yellow. Immune cells near the 
border co-express IDO, PD-L1, CD11c and CD11b. Tumor cells express HLA-DR, with a 
gradient from the boundary inwards.
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Figure 7: Tumor-Immune mixing and immune-regulatory expression patterns relate to overall 
survival
(A) Cartoon depicting three archetypes of tumor-immune composition and organization in 
TNBC. Cold tumors have few immune cells, mainly macrophages. Mixed tumors have 
tumor and immune cells mixed together. IDO and PD-L1, if expressed, are expressed 
primarily on tumor cells and PD-1 on CD8+ T cells. In compartmentalized tumors, the 
immune and tumor cells are spatially segregated. Neutrophils are enriched near the border, 
whereas B-cells form secondary lymphoid structures further away. IDO and PD-L1 are 
expressed primarily on immune cells and PD-1 on CD4+ T cells. A subset of tumors express 
HLA-DR, with a gradient of HLA-DR and H3K9ac/H3K27me3 from the border towards the 
tumor center. (B) Kaplan-Meier curves showing survival as a function of time for patients 
with compartmentalized or mixed tumor- immune organizations. Hazards ratio (HR) and p-
value (P) were calculated using Cox regression analysis.
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Key resources table
 REAGENT or RESOURCE  SOURCE  IDENTIFIER
 Antibodies
 A full list of antibodies is provided in Table S1
 Biological Samples
 TNBC TMA was compiled by the Stanford Pathology
 Department
 Chemicals, Peptides, and Recombinant Proteins
 TBS IHC Wash Buffer with Tween 20  Cell Marque  Cat#935B-09
 PBS IHC Wash Buffer with Tween 20  Cell Marque  Cat#934B-09
 Target Retrieval Solution, pH 9, (3:1)  Agilent (Dako)  Cat#S2375
 Avidin/Biotin Blocking Kit  Biolegend  Cat#927301
 Gelatin (cold water fish skin)  Sigma-Aldrich  Cat#G7765–250
 Xylene Histological grade  Sigma-Aldrich  Cat#534056–500
 Glutaraldehyde 8% Aqueous Solution EM Grade  EMS  Cat#16020
 Normal Donkey serum  Sigma-Aldrich  Cat#D9663–10ML
 Bovine Albumin (BSA)  Fisher  Cat#BP1600–100
 Centrifugal filters (0.1 μm)  Millipore  Cat#UFC30VV00
 Critical Commercial Assays
 Maxpar X8 Antibody labeling kit  Fluidigm  Cat#2011XXX
 MIBItag Conjugation Kit  IONpath  Cat#600XXX
 ImmPRESS UNIVERSAL (Anti-Mouse/Anti-Rabbit) IgG
 KIT (HRP)
 Vector Laboratories  Cat#MP-7500–15
 ImmPACT DAB (For HRP Substrate)  Vector Laboratories  Cat#SK-4105
 Deposited Data
 https://mibi-share.ionpath.com  All the data of the
 study
 Software and Algorithms
 Data analysis was done using Matlab 2016  Mathworks
 https://github.com/lkeren/MIBIAnalysis  Analysis code
 https://hub.docker.com/r/vanvalen/deepcell-mibi  Segmentation code
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